ASCO GU 2021: Combinations of lenvatinib plus pembrolizumab or everolimus improved survival in untreated patients with advanced kidney cancer
Results from the phase 3 CLEAR study, presented at the [...]
Lenvatinib plus everolimus for non clear cell kidney cancer
Treating non-clear cell renal cell carcinoma (RCC) is challenging because [...]
Everolimus and bevacizumab for advanced papillary kidney cancer
In this phase 2 clinical trial, a combination of everolimus [...]
Phase 1 trial of vorolanib plus everolimus for advanced kidney cancer
A new combination of vorolanib, a tyrosine kinase inhibitor plus [...]
ASCO GU 2020: Randomised clinical trial of HIF-2α inhibitor in patients with advanced kidney cancer
A randomised clinical trial of hypoxia inducible factor 2α (HIF-2α) [...]
ASCO GU 2020: Five-year survival data for metastatic kidney cancer patients treated with nivolumab
Five-year follow-up results from the phase 3 CheckMate-025 study, which [...]
Generic everolimus approved by the FDA
The US Food and Drug Administration (FDA) has approved generic [...]
Panobinostat plus everolimus not effective in metastatic kidney cancer
A recent phase I clinical trial assessed the combination of [...]
SMC approves lenvatinib plus everolimus combination for second-line treatment of advanced kidney cancer
We are delighted to announce that the Scottish Medicines Consortium (SMC), [...]
ESMO 2019: Results from ENTRATA clinical trial with telaglenastat plus everolimus for pre-treated kidney cancer
Results from the ENTRATA clinical trial to assess telaglenastat in [...]
